000			nab a22 7a 4500
999			_c16360 _d16360
003			PC16360
005			20210423125907.0
008			210420b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9539 _aRuilope Urioste, Luis Miguel _eNefrología
100			_92029 _aCerezo Olmos, César _eNefrología
245	0	0	_aInfluence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study. _h[artículo]
260			_bEuropean heart journal, _c2014
300			_a35(5):299-306.
500			_aFormato Vancouver: Calvo-Bonacho E, Ruilope LM, Sánchez-Chaparro MA, Cerezo C, Catalina-Romero C, Martínez-Muñoz P et al. A. Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study. Eur Heart J. 2014 Feb;35(5):299-306.
501			_aPMID: 23641010
504			_aContiene 28 referencias
520			_aAims: We investigated the potential influence of a moderate-to-high cardiovascular (CV) risk (CVR) (defined as a Systematic COronary Risk Evaluation model, or SCORE ≥ 4%), in the absence of an established CV disease, on the duration and cost of CV and non-CV sick leave (SL) resulting from common and occupational accidents or diseases. Methods and results: We conducted a prospective cohort study on 690 135 workers with a 1-year follow-up and examined CV- and non-CV-related SL episodes. To obtain baseline values, CVR factors were initially assessed at the beginning of the year during routine medical examination. The CVR was calculated with the SCORE charts for all subjects. Moderate-to-high CVR was defined as SCORE ≥ 4%. A baseline SCORE ≥ 4% was associated with a higher risk for long-term CV and non-CV SL, as revealed by follow-up assessment. This translated into an increased cost, estimated at €5 801 464.18 per year. Furthermore, pharmacological treatment for hypertension or hyperlipidaemia was significantly associated with longer SL duration. Conclusion: Moderate-to-high CVR in asymptomatic subjects was significantly associated with the duration and cost of CV and non-CV SL. These results constitute the first body of evidence that the SCORE charts can be used to identify people with a non-established CV disease, which might ultimately translate into more lost workdays and therefore increased cost for society.
710			_986 _aServicio de Nefrología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16360.pdf _ySolicitar documento
942			_2ddc _cART _n0